Major depressive disorder in children and adolescents is a serious health problem, with effects that reach into schoolwork, family life and friendships, and it carries real risks to wellbeing and, in the most serious cases, to life itself. A 2023 review found that as many as 15% of children and adolescents experience major depressive disorder at some point, and that when treatment starts with a standard antidepressant, known as an SSRI, around 30 to 40% do not respond adequately to that first medication.
For young people in this position, the review found that the only treatment approach with a solid evidence base is switching to a different SSRI, combined with cognitive behavioural therapy. Other emerging options, including ketamine, transcranial magnetic stimulation, other forms of psychotherapy, and combinations of medication with additional interventions, are being explored, but the review is clear that these need further long-term, controlled research before their safety and effectiveness in this age group can be established.
This is a hard but honest picture: many young people do not respond to the first treatment tried, and much of what might help next is still being tested. If your child or teenager is struggling with depression, professional support can help identify the right next step. Gecko House is here to help.
What the review covered
This 2023 review had a narrow focus: treatment-resistant depression in children and adolescents. That means cases of major depressive disorder (MDD) that do not respond adequately to standard first-line treatment. It draws together existing evidence on how common this problem is, what the current evidence-based options are, and what newer treatments are being investigated.
What it found
The review describes major depressive disorder in children and adolescents as a significant health problem, causing profound impairments across social, academic and family functioning, along with substantial morbidity and mortality risk. Up to 15% of children and adolescents experience MDD, it reports. Of those who begin treatment with a selective serotonin reuptake inhibitor (SSRI), the first-line medication for paediatric depression, around 30 to 40% fail to respond adequately.
For this group, the review states that the only recommendation with a solid evidence base is switching to a different SSRI, combined with augmentation using cognitive behavioural therapy. Beyond this, the review discusses a range of newer or less established approaches, including ketamine, transcranial magnetic stimulation, forms of psychotherapy other than cognitive behavioural therapy, and combined pharmacotherapy alongside other interventions. It is explicit that all of these require further longitudinal, controlled trials to establish their efficacy and safety in this vulnerable age group, and stops short of recommending them for routine use.
Why it matters
For families of a young person who has not improved on their first antidepressant, this review offers an honest picture rather than a reassuring one. Non-response is common. It affects close to a third to nearly half of young people who start SSRI treatment, and it is not a sign that nothing more can be done. What it does mean is that the next evidence-based step, switching medication and adding cognitive behavioural therapy, is a considered, established approach rather than a fallback. Newer options are not yet ready to take its place. Families should be cautious about treatments presented as breakthroughs for adolescent depression, given that the evidence for their safety and effectiveness in this age group is still developing.
Its limits
As a review article rather than a new clinical trial, this paper synthesises existing research and its conclusions depend on the quality and scope of the studies it summarises. It does not report original outcome data of its own, and its main message about newer treatments is precisely that the evidence is not yet sufficient to draw firm conclusions. It also focuses on medication and combined approaches, particularly with respect to what should happen after an SSRI has failed, rather than offering a broader account of the psychological therapies available for adolescent depression more generally.
Depression in a child or teenager, especially depression that has not responded to an initial treatment, deserves a proper, individualised assessment. If this describes your family's experience, reaching out to a psychologist can help clarify the options that are right for your child.